Global /United Kingdom /Healthcare /Drug Manufacturers - General /POLB

Poolbeg Pharma PLC

POLB

• LSE: POLB • Delayed

4GBX -1.4%

0.0569 USD

As of 5 June 2026, Poolbeg Pharma PLC has a market cap of $40.68M USD, ranking #32055 globally and #724 in the United Kingdom. It ranks #2897 in the Healthcare sector, and #1004 in the Drug Manufacturers - General industry.

Global Rank

32055

Country Rank

724

Sector Rank

2897

Industry Rank

1004

Key Stats

Market Cap

$40.68MUSD

30.32M GBP

Enterprise Value

$27.33MUSD

20.36M GBP

EBITDA (TTM)

-$7.97MUSD

-5.94M GBP

Net Income (TTM)

-$7.64MUSD

-5.7M GBP

PB Ratio

3.5

Company Profile

Country (HQ)

United Kingdom

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Jeremy Skillington open_in_new

Employees

Founded

2021

Website

poolbegpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.4%	0.5%	2.4%	6.2%	10%	7.5%	48%	-40%	-25%

News

Markets

Exchange	Ticker	Price	Quotes
London Stock Exchange (LSE / LON) MIC: XLON PRIMARY	POLB Poolbeg Pharma PLC Ordinary Shares ISIN: GB00BKPG7Z60 Shares Out.: Shares Outstanding: 705.104M¹ Shares Float: 501.33M² TV: TradingView: LSE: POLB SA: Stock Analysis: LON: POLB YF: Yahoo Finance: POLB.L GF: Google Finance: LON: POLB BA: Barron's: POLB MS: Morningstar: XLON: POLB	4 GBX	TV: TradingView: LSE: POLB SA: Stock Analysis: LON: POLB YF: Yahoo Finance: POLB.L GF: Google Finance: LON: POLB BA: Barron's: POLB MS: Morningstar: XLON: POLB
OTC Markets (OTCMKTS / OTC) MIC: OTCM	POLBF Poolbeg Pharma PLC Ordinary Shares ISIN: GB00BKPG7Z60 Shares Out.: Shares Outstanding: 697.2M¹ Shares Float: 442.153M² TV: TradingView: OTC: POLBF SA: Stock Analysis: OTC: POLBF YF: Yahoo Finance: POLBF GF: Google Finance: OTCMKTS: POLBF BA: Barron's: POLBF MS: Morningstar: PINX: POLBF	0.0425 USD	TV: TradingView: OTC: POLBF SA: Stock Analysis: OTC: POLBF YF: Yahoo Finance: POLBF GF: Google Finance: OTCMKTS: POLBF BA: Barron's: POLBF MS: Morningstar: PINX: POLBF

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Poolbeg Pharma PLC

Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

Similar Companies

Industry: Drug Manufacturers - General (United Kingdom)

Name	Market Cap (USD) diff.	PE	Country
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 711K%	27.6	United Kingdom
GSK plc LSE: GSK	$108.62B 80.96B GBP 267K%	14.6	United Kingdom
Haleon plc LSE: HLN	$41.88B 31.22B GBP 103K%	19.0	United Kingdom
Roivant Sciences Ltd. NASDAQ: ROIV	$19.69B 48K%	-	United Kingdom
Centessa Pharmaceuticals plc NASDAQ: CNTA	$6.1B 15K%	-	United Kingdom
Kiniksa Pharmaceuticals International, plc NASDAQ: KNSA	$4.07B 10K%	58.4	United Kingdom

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 2M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 886K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 795K%	19.9	Switzerland
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 679K%	20.5	Switzerland
Merck & Co., Inc. NYSE: MRK	$274.03B 674K%	15.1	United States

chevron_leftBack